Selected research
Industry Research
mRNA Vaccine Drugs Development Services Industry Research Report 2026
Market perspective
The global mRNA Vaccine Drugs Development Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the mRNA Vaccine Drugs Development Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the mRNA Vaccine Drugs Development Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the mRNA Vaccine Drugs Development Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of mRNA Vaccine Drugs Development Services include ReciBioPharm, Merck, Samsung Biologics, Thermo Fisher Scientific, Lonza, Ricoh Group, Aldevron, Wuxi Biologics and Genscript Probio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global mRNA Vaccine Drugs Development Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to mRNA Vaccine Drugs Development Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
mRNA Vaccine Drugs Development Services Market by Company
ReciBioPharm
Merck
Samsung Biologics
Thermo Fisher Scientific
Lonza
Ricoh Group
Aldevron
Wuxi Biologics
Genscript Probio
Novoprotein
Porton Advanced Solutions
Precision NanoSystems
mRNA Vaccine Drugs Development Services Segment by Type
mRNA Process Development Services
mRNA Synthesis Services
mRNA Drug Substance Purification Services
Others
mRNA Vaccine Drugs Development Services Segment by Application
Non-Replicating mRNA Vaccine Drugs
Self-Amplifying mRNA Vaccine Drugs
mRNA Vaccine Drugs Development Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccine Drugs Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccine Drugs Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccine Drugs Development Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of mRNA Vaccine Drugs Development Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Process Development Services
- mRNA Synthesis Services
- mRNA Drug Substance Purification Services
- Others
Applications
- Non-Replicating mRNA Vaccine Drugs
- Self-Amplifying mRNA Vaccine Drugs
Companies covered
- ReciBioPharm
- Merck
- Samsung Biologics
- Thermo Fisher Scientific
- Lonza
- Ricoh Group
- Aldevron
- Wuxi Biologics
- Genscript Probio
- Novoprotein
- Porton Advanced Solutions
- Precision NanoSystems
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 mRNA Vaccine Drugs Development Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 mRNA Process Development Services
- 2.2.3 mRNA Synthesis Services
- 2.2.4 mRNA Drug Substance Purification Services
- 2.2.5 Others
- 2.3 mRNA Vaccine Drugs Development Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Non-Replicating mRNA Vaccine Drugs
- 2.3.3 Self-Amplifying mRNA Vaccine Drugs
- 2.4 Assumptions and Limitations
3 mRNA Vaccine Drugs Development Services Breakdown Data by Type
- 3.1 Global mRNA Vaccine Drugs Development Services Historic Market Size by Type (2021-2026)
- 3.2 Global mRNA Vaccine Drugs Development Services Forecasted Market Size by Type (2027-2032)
4 mRNA Vaccine Drugs Development Services Breakdown Data by Application
- 4.1 Global mRNA Vaccine Drugs Development Services Historic Market Size by Application (2021-2026)
- 4.2 Global mRNA Vaccine Drugs Development Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global mRNA Vaccine Drugs Development Services Market Perspective (2021-2032)
- 5.2 Global mRNA Vaccine Drugs Development Services Growth Trends by Region
- 5.2.1 Global mRNA Vaccine Drugs Development Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 mRNA Vaccine Drugs Development Services Historic Market Size by Region (2021-2026)
- 5.2.3 mRNA Vaccine Drugs Development Services Forecasted Market Size by Region (2027-2032)
- 5.3 mRNA Vaccine Drugs Development Services Market Dynamics
- 5.3.1 mRNA Vaccine Drugs Development Services Industry Trends
- 5.3.2 mRNA Vaccine Drugs Development Services Market Drivers
- 5.3.3 mRNA Vaccine Drugs Development Services Market Challenges
- 5.3.4 mRNA Vaccine Drugs Development Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top mRNA Vaccine Drugs Development Services Players by Revenue
- 6.1.1 Global Top mRNA Vaccine Drugs Development Services Players by Revenue (2021-2026)
- 6.1.2 Global mRNA Vaccine Drugs Development Services Revenue Market Share by Players (2021-2026)
- 6.2 Global mRNA Vaccine Drugs Development Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of mRNA Vaccine Drugs Development Services Head Office and Area Served
- 6.4 Global mRNA Vaccine Drugs Development Services Players, Product Type & Application
- 6.5 Global mRNA Vaccine Drugs Development Services Manufacturers Established Date
- 6.6 Global mRNA Vaccine Drugs Development Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 7.2 North America mRNA Vaccine Drugs Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 7.4 North America mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 8.2 Europe mRNA Vaccine Drugs Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 8.4 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 9.2 Asia-Pacific mRNA Vaccine Drugs Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 10.2 South America mRNA Vaccine Drugs Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 10.4 South America mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 11.2 Middle East & Africa mRNA Vaccine Drugs Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 ReciBioPharm
- 12.1.1 ReciBioPharm Company Information
- 12.1.2 ReciBioPharm Business Overview
- 12.1.3 ReciBioPharm Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio
- 12.1.5 ReciBioPharm Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.2.4 Merck mRNA Vaccine Drugs Development Services Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Samsung Biologics
- 12.3.1 Samsung Biologics Company Information
- 12.3.2 Samsung Biologics Business Overview
- 12.3.3 Samsung Biologics Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 12.3.5 Samsung Biologics Recent Developments
- 12.4 Thermo Fisher Scientific
- 12.4.1 Thermo Fisher Scientific Company Information
- 12.4.2 Thermo Fisher Scientific Business Overview
- 12.4.3 Thermo Fisher Scientific Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio
- 12.4.5 Thermo Fisher Scientific Recent Developments
- 12.5 Lonza
- 12.5.1 Lonza Company Information
- 12.5.2 Lonza Business Overview
- 12.5.3 Lonza Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.5.4 Lonza mRNA Vaccine Drugs Development Services Product Portfolio
- 12.5.5 Lonza Recent Developments
- 12.6 Ricoh Group
- 12.6.1 Ricoh Group Company Information
- 12.6.2 Ricoh Group Business Overview
- 12.6.3 Ricoh Group Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio
- 12.6.5 Ricoh Group Recent Developments
- 12.7 Aldevron
- 12.7.1 Aldevron Company Information
- 12.7.2 Aldevron Business Overview
- 12.7.3 Aldevron Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.7.4 Aldevron mRNA Vaccine Drugs Development Services Product Portfolio
- 12.7.5 Aldevron Recent Developments
- 12.8 Wuxi Biologics
- 12.8.1 Wuxi Biologics Company Information
- 12.8.2 Wuxi Biologics Business Overview
- 12.8.3 Wuxi Biologics Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 12.8.5 Wuxi Biologics Recent Developments
- 12.9 Genscript Probio
- 12.9.1 Genscript Probio Company Information
- 12.9.2 Genscript Probio Business Overview
- 12.9.3 Genscript Probio Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio
- 12.9.5 Genscript Probio Recent Developments
- 12.10 Novoprotein
- 12.10.1 Novoprotein Company Information
- 12.10.2 Novoprotein Business Overview
- 12.10.3 Novoprotein Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.10.4 Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio
- 12.10.5 Novoprotein Recent Developments
- 12.11 Porton Advanced Solutions
- 12.11.1 Porton Advanced Solutions Company Information
- 12.11.2 Porton Advanced Solutions Business Overview
- 12.11.3 Porton Advanced Solutions Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio
- 12.11.5 Porton Advanced Solutions Recent Developments
- 12.12 Precision NanoSystems
- 12.12.1 Precision NanoSystems Company Information
- 12.12.2 Precision NanoSystems Business Overview
- 12.12.3 Precision NanoSystems Revenue in mRNA Vaccine Drugs Development Services Business (2021-2026)
- 12.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio
- 12.12.5 Precision NanoSystems Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst